Search results
Results From The WOW.Com Content Network
The five main classes in the Vaughan Williams classification of antiarrhythmic agents are: Class I agents interfere with the sodium (Na +) channel. Class II agents are anti-sympathetic nervous system agents. Most agents in this class are beta blockers. Class III agents affect potassium (K +) efflux. Class IV agents affect calcium channels and ...
[1] [2] [3] Subgroup C01 is part of the anatomical group C Cardiovascular system. [4] Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC01. [5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
Class of antihypertensives that bind to and inhibit the angiotensin II receptor type 1 and thereby block the arteriolar contraction and sodium retention effects of renin–angiotensin system. Azilsartan medoxomil
Sodium channel blockers (1 C, 77 P) Pages in category "Antiarrhythmic agents" The following 59 pages are in this category, out of 59 total.
Class Ic antiarrhythmic agents markedly depress the phase 0 depolarization (decreasing V max). They decrease conductivity, but have a minimal effect on the action potential duration. Of the sodium channel blocking antiarrhythmic agents (the class I antiarrhythmic agents), the class Ic agents have the most potent sodium channel blocking effects.
The second Cardiac Arrhythmia Suppression Trial (CAST II) modified the enrollment criteria to include patients at higher risk for serious arrhythmia. [4] This included 1) patients enrolled within 4 to 90 days of a previous MI, 2) a left ventricular ejection fraction lower than 40%, 3) prior to enrollment, suppression of PVCs had occurred with the drugs (vs. placebo) using a double-blinded ...
Lorcainide (Lorcainide hydrochloride) is a Class 1c antiarrhythmic agent that is used to help restore normal heart rhythm and conduction in patients with premature ventricular contractions, ventricular tachycardiac [1] and Wolff–Parkinson–White syndrome. [2]
[1] Two distinct drug classes in which cardiotoxicity can occur are in anti-cancer and antiarrhythmic drugs. Anti-cancer drug classes that cause cardiotoxicity include anthracyclines, monoclonal antibodies, and antimetabolites. This form generally manifests as a progressive form of heart failure, but can also manifest as an harmful arrhythmia. [2]